Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eden Hands Keys To CDMO Unit Over To Bora Pharmaceuticals

Taiwanese Biologics Developer Will Maintain Relationship With Spun-Out Unit

Executive Summary

Eden Biologics has sold its CDMO business to Bora Pharmaceuticals’ recently-established biologics CDMO platform Bora Biologics. The firm appears keen to maintain a working relationship with its former unit following the sale.

You may also be interested in...



Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs

Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.

Former JHL Executives Face Prison Over Trade Secrets Theft

Two former JHL Biotech executives have been handed prison sentences after pleading guilty to a charge of conspiracy to commit theft of trade secrets and wire fraud, in relation to the Taiwanese firm’s development of multiple biosimilars.

JHL Biotech Executives Convicted Over Trade Secrets Theft

Two former JHL Biotech executives, Racho Jordanov and Rose Lin, have been convicted in the US of conspiracy to commit trade secret theft and wire fraud after submitting plea agreements. Meanwhile, the company – now named Eden Biologics – has just announced a change of CEO.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel